Agenus Inc financial data

Symbol
AGEN on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3 Forbes Road, Lexington, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
ANTIGENICS INC /DE/ (to 1/5/2011)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 30.7 % -66.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.5M shares -93.9%
Common Stock, Shares, Outstanding 21.7M shares
Entity Public Float 584M USD +7.24%
Common Stock, Value, Issued 217K USD -94.3%
Weighted Average Number of Shares Outstanding, Basic 21.6M shares +14%
Weighted Average Number of Shares Outstanding, Diluted 21.6M shares +14%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 160M USD +59%
Cost of Revenue 628K USD -94%
Research and Development Expense 188M USD -14.8%
General and Administrative Expense 72.1M USD -12.7%
Operating Income (Loss) -98.8M USD +53.6%
Nonoperating Income (Expense) 5.85M USD +85.5%
Earnings Per Share, Basic 2.2 USD/shares +6.38%
Earnings Per Share, Diluted 2.2 USD/shares +6.38%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44.8M USD -57.9%
Cash, Cash Equivalents, and Short-term Investments 44.8M USD -57.9%
Accounts Receivable, after Allowance for Credit Loss, Current 207K USD -79.9%
Other Assets, Current 2.81M USD +20.7%
Assets, Current 50.2M USD -60.1%
Property, Plant and Equipment, Net 124M USD -10.9%
Operating Lease, Right-of-Use Asset 28.6M USD -4.68%
Intangible Assets, Net (Excluding Goodwill) 3.96M USD -12.1%
Goodwill 24.7M USD +0.11%
Other Assets, Noncurrent 6.6M USD -40.4%
Assets 238M USD -28.9%
Accounts Payable, Current 45.9M USD +12.3%
Accrued Liabilities, Current 36.7M USD -2.48%
Contract with Customer, Liability, Current 13M USD +31.5%
Liabilities, Current 271M USD +36.4%
Contract with Customer, Liability, Noncurrent 1.14M USD 0%
Operating Lease, Liability, Noncurrent 55.2M USD -12.7%
Other Liabilities, Noncurrent 777K USD -90.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.35M USD -31%
Retained Earnings (Accumulated Deficit) -2.14B USD -11.9%
Stockholders' Equity Attributable to Parent -292M USD -126%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -272M USD -136%
Liabilities and Equity 238M USD -28.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.2M USD +34.7%
Net Cash Provided by (Used in) Financing Activities 14.8M USD -73.6%
Net Cash Provided by (Used in) Investing Activities 229K USD
Common Stock, Shares Authorized 800M shares 0%
Common Stock, Shares, Issued 21.7M shares -94.3%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -23.3M USD -67.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 667K USD -19.6%
Deferred Tax Assets, Valuation Allowance 376M USD +8.23%
Cash and Cash Equivalents, Period Increase (Decrease) -44.2M USD -327%
Deferred Tax Assets, Gross 392M USD +7.54%
Operating Lease, Liability 65.1M USD -0.26%
Payments to Acquire Property, Plant, and Equipment 35K USD -98.1%
Lessee, Operating Lease, Liability, to be Paid 119M USD -6.05%
Property, Plant and Equipment, Gross 195M USD +4.42%
Operating Lease, Liability, Current 2.43M USD -5.16%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10.1M USD +2.92%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.89M USD +26.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 54.2M USD -12.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 9.85M USD -1.95%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.43M USD +4.32%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10.1M USD +2.99%
Additional Paid in Capital 1.85B USD +3.84%
Deferred Tax Assets, Net of Valuation Allowance 15.8M USD -6.5%
Share-based Payment Arrangement, Expense 28.1M USD +31.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%